Regulatory

Kyowa Kirin secures FDA approval for Crysvita dosing update

Pharmaceutical Technology

Kyowa Kirin has received approval from the FDA for a dosing update to the Crysvita prescribing information, introducing a new option for adults with XLH.

Rare Disease

Read full story

pharminent May 15, 2026 (Last updated: May 21, 2026)

Pharmaceutical Technology

Kyowa Kirin has received approval from the FDA for a dosing update to the Crysvita prescribing information, introducing a new option for adults with XLH.

Rare Disease

Read full story

Related Stories

FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients

FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy

Replimune gives cancer immunotherapy a third try after FDA leadership shakeup

You May Have Missed

Eli Lilly issues data sharing ultimatum to 340B hospitals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma

ASCO26: In vivo oncology approaches continue to show promise